$0.95
2.63%
Downside
Day's Volatility :4.61%
Upside
2.03%
62.11%
Downside
52 Weeks Volatility :81.25%
Upside
50.52%
Period | Veru Inc | Sector (Consumer Staples) | Index (Russel 2000) |
---|---|---|---|
3 Months | -25.35% | 2.8% | 0.0% |
6 Months | 120.41% | 7.0% | 0.0% |
1 Year | -22.3% | 2.3% | 0.0% |
3 Years | -86.32% | 8.6% | -20.2% |
Market Capitalization | 138.5M |
Book Value | $0.31 |
Earnings Per Share (EPS) | -0.35 |
PEG Ratio | 0.0 |
Wall Street Target Price | 3.4 |
Profit Margin | -289.01% |
Operating Margin TTM | -239.13% |
Return On Assets TTM | -40.76% |
Return On Equity TTM | -125.82% |
Revenue TTM | 13.5M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | -37.2% |
Gross Profit TTM | 30.6M |
EBITDA | -46.0M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.27 |
EPS Estimate Next Year | -0.3 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 257.89%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 15.9M | ↑ 16.18% |
Net Income | -23.9M | ↑ 262.04% |
Net Profit Margin | -150.89% | ↓ 102.47% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.8M | ↑ 100.47% |
Net Income | -12.0M | ↓ 49.8% |
Net Profit Margin | -37.79% | ↑ 113.1% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.6M | ↑ 33.92% |
Net Income | -19.0M | ↑ 57.88% |
Net Profit Margin | -44.55% | ↓ 6.76% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 61.3M | ↑ 43.83% |
Net Income | 7.4M | ↓ 138.97% |
Net Profit Margin | 12.07% | ↑ 56.62% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 39.4M | ↓ 35.76% |
Net Income | -83.8M | ↓ 1232.97% |
Net Profit Margin | -212.88% | ↓ 224.95% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 16.3M | ↓ 58.59% |
Net Income | -93.1M | ↑ 11.12% |
Net Profit Margin | -571.2% | ↓ 358.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↓ 3.12% |
Net Income | -36.8M | ↓ 10.19% |
Net Profit Margin | -1.5K% | ↑ 115.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.6M | ↑ 162.62% |
Net Income | -38.8M | ↑ 5.29% |
Net Profit Margin | -589.02% | ↑ 880.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.3M | ↓ 49.27% |
Net Income | 6.3M | ↓ 116.28% |
Net Profit Margin | 188.98% | ↑ 778.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.9M | ↑ 15.59% |
Net Income | -23.8M | ↓ 476.42% |
Net Profit Margin | -615.43% | ↓ 804.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.1M | ↓ 44.57% |
Net Income | -8.3M | ↓ 65.18% |
Net Profit Margin | -386.6% | ↑ 228.83% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.1M | ↑ 0.0% |
Net Income | -8.3M | ↑ 0.0% |
Net Profit Margin | -386.6% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 48.5M | ↓ 12.39% |
Total Liabilities | 19.0M | ↑ 176.82% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 53.6M | ↑ 10.68% |
Total Liabilities | 21.3M | ↑ 12.25% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 51.5M | ↓ 3.89% |
Total Liabilities | 21.4M | ↑ 0.64% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 178.1M | ↑ 245.62% |
Total Liabilities | 25.9M | ↑ 20.62% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 136.1M | ↓ 23.59% |
Total Liabilities | 55.3M | ↑ 113.85% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 50.6M | ↓ 62.83% |
Total Liabilities | 32.8M | ↓ 40.65% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 103.8M | ↓ 23.76% |
Total Liabilities | 54.7M | ↓ 1.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 70.3M | ↓ 32.31% |
Total Liabilities | 53.5M | ↓ 2.1% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 75.2M | ↑ 7.03% |
Total Liabilities | 40.8M | ↓ 23.78% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 50.6M | ↓ 32.71% |
Total Liabilities | 32.8M | ↓ 19.59% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 80.6M | ↑ 59.24% |
Total Liabilities | 29.0M | ↓ 11.73% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 80.6M | ↑ 0.0% |
Total Liabilities | 29.0M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.5M | ↓ 1274.72% |
Investing Cash Flow | -50.7K | ↓ 43.95% |
Financing Cash Flow | 12.1M | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.5M | ↓ 52.49% |
Investing Cash Flow | -108.5K | ↑ 114.23% |
Financing Cash Flow | 8.1M | ↓ 32.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.9M | ↓ 64.81% |
Investing Cash Flow | -105.8K | ↓ 2.54% |
Financing Cash Flow | 9.3M | ↑ 14.76% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.6M | ↑ 706.75% |
Investing Cash Flow | 14.6M | ↓ 13926.92% |
Financing Cash Flow | 109.7M | ↑ 1076.04% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.5M | ↑ 205.09% |
Investing Cash Flow | 4.3M | ↓ 70.82% |
Financing Cash Flow | 1.1M | ↓ 99.03% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.5M | ↑ 65.4% |
Investing Cash Flow | -285.6K | ↑ 91.9% |
Financing Cash Flow | 1.6M | ↑ 133.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.6M | ↓ 26.0% |
Investing Cash Flow | -141.6K | ↓ 50.42% |
Financing Cash Flow | 2.3M | ↑ 45.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.4M | ↓ 27.88% |
Investing Cash Flow | 6.0M | ↓ 4319.54% |
Financing Cash Flow | 5.2M | ↑ 128.0% |
Sell
Neutral
Buy
Veru Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Veru Inc | 18.66% | 120.41% | -22.3% | -86.32% | -58.42% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Veru Inc | NA | NA | 0.0 | -0.27 | -1.26 | -0.41 | NA | 0.31 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Veru Inc | Buy | $138.5M | -58.42% | NA | -289.01% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Veru Inc
Revenue is down for the last 3 quarters, 3.86M → 2.14M (in $), with an average decrease of 22.3% per quarter
Netprofit is up for the last 3 quarters, -23.76M → -8.27M (in $), with an average increase of 93.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 83.9%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 272.8%
Adage Capital Partners Gp LLC
Perceptive Advisors LLC
Vanguard Group Inc
Rosalind Advisors, Inc.
Octagon Capital Advisors LP
Morgan Stanley - Brokerage Accounts
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Organization | Veru Inc |
Employees | 189 |
CEO | Dr. Mitchell S. Steiner F.A.C.S., M.D. |
Industry | Consumer Non-Durables |
A Spac I Acquisition Corp
$0.95
+0.05%
Keyarch Acquisition Corp
$0.95
+0.05%
Connexa Sports Technologies Inc
$0.95
+0.05%
Us Value Etf
$0.95
+0.05%
First Wave Biopharma Inc
$0.95
+0.05%
Global X Msci Next Emerging
$0.95
+0.05%
Fat Projects Acquisition Corp
$0.95
+0.05%
Capital Link Global Fintech
$0.95
+0.05%
Applied Uv Inc
$0.95
+0.05%